WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
Waldenstrom Macroglobulinemia is a rare lymphoproliferative disorder with distinctive clinical features. Diagnostic and prognostic charactrization in WM significantly changed with the discovery of two molecular markers: MYD88 and CXCR4. Mutational status of these latter influences both clinical pres...
Main Authors: | Maddalena Mazzucchelli, Anna Maria Frustaci, Marina Deodato, Roberto Cairoli, Alessandra Tedeschi |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2018-01-01
|
Series: | Mediterranean Journal of Hematology and Infectious Diseases |
Subjects: | |
Online Access: | https://www.mjhid.org/index.php/mjhid/article/view/3183 |
Similar Items
-
Ibrutinib-Induced Pancreatitis in Patients with Waldenstrom Macroglobulinemia
by: Nurhilal Büyükkurt, et al.
Published: (2023-06-01) -
Should Patients with Waldenström Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy?
by: Marina Deodato, et al.
Published: (2022-10-01) -
A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia
by: Rayan Kaedbey, et al.
Published: (2022-09-01) -
Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy
by: Andrea Aiello, et al.
Published: (2017-01-01) -
The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
by: Obada Ababneh, et al.
Published: (2022-05-01)